Study suggests patients with lung cancer who carry specific HER2 mutations may benefit from certain anti-HER2 treatments
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced ...
Cancer
Apr 22, 2013 |
not rated yet |
0
Breast cancer gene provides vital clue to bowel cancer drug resistance
Having too many copies of a gene linked to breast cancer might be the reason why some bowel cancer patients fail to respond to certain targeted drugs, according to a study published in the British Journal of ...
Cancer
Feb 20, 2013 |
not rated yet |
0
|
Existing drugs may help more breast cancer patients
More patients can benefit from highly effective breast cancer drugs that are already available, according to DNA sequencing studies by researchers at Washington University School of Medicine in St. Louis ...
Cancer
Dec 07, 2012 |
not rated yet |
0
Preliminary findings about whole-genome sequencing of triple-negative breast cancer presented
Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.
Cancer
Apr 02, 2012 |
not rated yet |
0
Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Cancer
Jan 16, 2012 |
5 / 5 (2) |
0
|
Scientists identify overactive genes in aggressive breast cancers
Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that ...
Cancer
Jun 01, 2011 |
not rated yet |
0
|
